

EMLc

ATC codes: C03CA01

Indication	Heart failure <span style="background-color: #00AEEF; color: white; padding: 2px 5px;">ICD11 code: BD0Z</span>
INN	Furosemide
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	The square box does not apply to the listing of furosemide on the EMLc
Formulations	Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule ; 10 mg per mL in 5 mL ampoule Oral > Liquid: 20 mg per 5 mL (EMLc) ; 50 mg per 5 mL (EMLc) Oral > Solid > tablet: 40 mg ; 20 mg
EML status history	First added in 2005 (TRS 933) Changed in 2007 (TRS 950) Changed in 2021 (TRS 1035) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	bumetanide (ATC codes: C03CA02) torasemide (ATC codes: C03CA04)
Patent information	Patents have expired in most jurisdictions <a href="#">Read more about patents.</a> 
Wikipedia	<a href="#">Furosemide</a> 
DrugBank	<a href="#">Furosemide</a> 

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of furosemide (injection 10 mg/mL in 5 mL; tablet 20 mg (EML and EMLc); oral liquid 50 mg/5 mL (EMLc). The Committee also recommended the removal of furosemide 10 mg tablets from the EMLc.

